[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res; 2002 Jul;8(7):2286-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
  • PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers.
  • We investigated whether ERCC1 mRNA expression levels were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC).
  • EXPERIMENTAL DESIGN: Response and survival were correlated with the level of ERCC1 expression in 56 patients with advanced (stage IIIb or IV) NSCLC treated as part of a multicenter randomized trial with Gem 1250 mg/m(2) days 1 and 8 plus CDDP 100 mg/m(2) on day 1 every 3 weeks. mRNA was isolated from paraffin-embedded pretreatment primary tumor specimens, and relative expression levels of ERCC1/beta-actin were measured using a quantitative reverse transcription-PCR (Taqman) system.
  • There were no significant differences in ERCC1 levels by gender, age, performance status, weight loss, or tumor stage.
  • CONCLUSIONS: These data suggest that ERCC1 expression is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / mortality. DNA-Binding Proteins. Deoxycytidine / analogs & derivatives. Endonucleases. Lung Neoplasms / mortality. Proteins / genetics
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12114432.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 62505; United States / NCI NIH HHS / CA / CA 63265; United States / NCI NIH HHS / CA / CA71716; United States / NCI NIH HHS / CM / CM 17101
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proteins; 0 / RNA, Messenger; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol; 2008 Dec;19(4):223-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.
  • OBJECTIVE: To verify whether it can be justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only.
  • METHODS: This study included all consecutive patients with stage IIIC epithelial ovarian cancer who underwent upfront cytoreductive surgery according to the FIGO guideline followed by platinum based chemotherapy from September 1989 to September 2006 at Asan Medical Center.
  • Median follow-up time was 37 months (range, 6-181 months).
  • Forty-one patients were allocated to stage IIIC by positive nodes only.
  • Patients with stage IIIC disease due to positive nodes only had significantly longer DFS and OS compared to other stage IIIC patients (p<0.001 and p<0.001).
  • The DFS and OS of these patients was significantly better than those of other stage IIIC patients who achieved complete or optimal cytoreduction (p<0.001 and p<0.001).
  • The outcome was even better than that of stage IIIA and IIIB patients (p<0.05 and p<0.05).
  • CONCLUSION: Patients with stage IIIC epithelial ovarian cancer due to positive nodes only had a more favorable prognosis compared to other stage IIIC patients.
  • Therefore, reevaluation of the current FIGO staging system for stage IIIC epithelial ovarian cancer is required.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):154-6 [17614126.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):781-2 [17141679.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):797-801 [17052746.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):237-41 [10329040.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1555-60 [9781949.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):467-72 [9190977.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):345-52 [7705667.001]
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):108-10 [7959250.001]
  • [Cites] Am J Obstet Gynecol. 1994 Feb;170(2):656-62 [8116728.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):150-4 [8276287.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):103-6 [2010101.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(1):36-9 [3345782.001]
  • [Cites] Gynecol Oncol. 1987 Jul;27(3):368-72 [3623232.001]
  • [Cites] Cancer. 1985 May 1;55(9):2019-25 [3978582.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Am J Obstet Gynecol. 1974 Aug 15;119(8):1013-7 [4847438.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1161-3 [11870155.001]
  • (PMID = 19471577.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676474
  • [Keywords] NOTNLM ; Epithelial ovarian cancer / Lymph node metastasis / Prognosis / Stage IIIC
  •  go-up   go-down


3. Tserkezoglou A, Kontou S, Hatjieleftheriou G, Nikolaidou ME, Plataniotis G, Apostolikas N, Magiakos G: Solitary parenchymal splenic recurrence of ovarian adenocarcinoma: a case report and review of the literature. Anticancer Res; 2005 Mar-Apr;25(2B):1471-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary parenchymal splenic recurrence of ovarian adenocarcinoma: a case report and review of the literature.
  • We report a rare case of solitary parenchymal splenic recurrence of epithelial ovarian cancer which developed 27 months after the initial treatment.
  • The patient, a 53-year-old woman, with a history of breast cancer, underwent total abdominal hysterectomy bilateral salpingo-ophorectomy (TAH & BSO), omentectomy and pelvic lymph node sampling for a serous carcinoma of the ovaries (stage IIIB).
  • She subsequently received 6 cycles of cisplatinum chemotherapy.
  • Histopathological evaluation revealed metastatic parenchymal disease consistent with recurrent ovarian cancer.
  • Isolated parenchymal splenic lesions are very rare and may occur as a late recurrence in epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Cisplatin / therapeutic use. Splenic Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Hysterectomy. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865107.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 45
  •  go-up   go-down


Advertisement
4. Yokoyama Y, Futagami M, Higuchi T, Mizunuma H: Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. Eur J Gynaecol Oncol; 2006;27(4):437-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report.
  • We examined pharmacokinetics of paclitaxel and carboplatin in a FIGO Stage IIIb ovarian cancer patient with hemodialysis-dependent chronic renal failure.
  • The patient suffered from recurrence of the disease after treatment with optimal debulking surgery and postoperative chemotherapy consisting of cisplatin, epirubicin and cyclophosphamide, and she was treated with combined paclitaxel and carboplatin as second-line chemotherapy.
  • The carboplatin dose was chosen to produce a target area under the concentration/time curve (AUC) of 5.0 microg-min/ml according to a published formula.
  • Four-hour hemodialysis was started 24 hours and 16 hours after the end of carboplatin administration in the first and second courses of the chemotherapy, respectively.
  • Pharmacokinetic studies showed that the AUCs of free platinum were 8.03 and 5.69 microg-min/ml in the first and second courses of the chemotherapy, respectively, suggesting that the AUC of carboplatin is affected by hemodialysis.
  • The evidence suggests that even patients with chronic renal failure can undergo combination chemotherapy of paclitaxel and carboplatin without suffering any severe adverse effects by determining the time to start hemodialysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Ovarian Neoplasms / metabolism. Renal Dialysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009648.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Gori J, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, Felci N: Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):233-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal hyperthermic chemotherapy in ovarian cancer.
  • We investigated the effect of intraperitoneal hyperthermic perfusion chemotherapy as consolidation therapy in stage IIIB-IIIC ovarian cancer, following cytoreductive surgery and systemic chemotherapy (cisplatin-cyclophosphamide--six cycles).
  • Disease-free survival, overall survival, and side effects were compared with a control group of patients who refused a second-look surgery and intraperitoneal chemotherapy.
  • In a multicenter prospective trial, 29 patients with complete or optimal cytoreductive surgery and systemic treatment were included in the consolidation group and received intraperitoneal hyperthermic perfusion chemotherapy.
  • Intraperitoneal hyperthermic perfusion chemotherapy was locally and systemically well tolerated.
  • The consolidation therapy group showed a better 5-year survival rate and lower recurrent disease rate, but differences were not statistically significant.
  • Our results suggest that intraperitoneal hyperthermic perfusion chemotherapy is a feasible, well-tolerated, and promising alternative as consolidation therapy in ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Hyperthermia, Induced. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823105.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T: [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1243-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
  • Clear-cell carcinoma of the ovary is a highly malignant neoplasm.
  • Survival of patients in the advanced stage is poor, and the best treatment is not clear.
  • We report here a case of a 57-year-old woman who had Stage IIIb advanced clearcell carcinoma of the ovary.
  • After the operation she was placed on induction and maintenance chemotherapy with a combination of irinotecan(CPT-11)(60 mg/m2, day 1, 15)plus cisplatin(CDDP)(60 mg/m2, day 1).
  • Considering the poor prognosis of clear-cell carcinoma, this regimen is thought to be effective for advanced clear-cell carcinoma of the ovary.
  • It is important to check brain metastases under maintenance chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Picone O, Lhommé C, Tournaire M, Pautier P, Camatte S, Vacher-Lavenue MC, Castaigne D, Morice P: Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review. Gynecol Oncol; 2004 Aug;94(2):600-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review.
  • BACKGROUND: To report a case of successful management of a FIGO stage III endometrioid carcinoma of the ovary diagnosed during pregnancy at 22 weeks of gestation and treated with initial chemotherapy while preserving the pregnancy.
  • At the same time, a radical hysterectomy, omentectomy, pelvic and paraaortic lymphadenectomies and peritonectomies were carried out.
  • The patient underwent seven postoperative courses of chemotherapy (carboplatin + paclitaxel regimen) after radical surgery.
  • CONCLUSION: Chemotherapy during pregnancy with preservation of the fetus could be considered and should be discussed in case of epithelial ovarian cancer (EOC) diagnosed during the second trimester of the pregnancy.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297214.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


8. Tsolakidis D, Amant F, Van Gorp T, Leunen K, Neven P, Vergote I: The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer; 2010 May;20(4):542-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
  • OBJECTIVES: The purpose of this retrospective study was to evaluate diaphragmatic surgery in achieving optimal cytoreductive results and its associated complications during interval debulking surgery in patients with advanced ovarian cancer.
  • METHODS: After retrospective review of medical records, diaphragmatic surgery was performed in 74 of 128 consecutive patients with advanced epithelial ovarian cancer who underwent interval debulking, between September 1993 and December 2007.
  • RESULTS: Two patients (2.7%) had International Federation of Gynecology and Obstetrics stage IIIB disease; 46 (62.16%), stage IIIC; and 26 (35.13%), stage IV.
  • After 3 to 4 cycles of neoadjuvant platinum-based chemotherapy, the diaphragmatic disease was coagulated in 43 patients (58.10%) and was only stripped in 10 (13.51%); in 19 patients (25.67%), a combination of these techniques was applied; and in 2 (2.70%), the disease was resected, with the adjacent infiltrated part of the diaphragmatic muscle and the pleura above it.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diaphragm / surgery. Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Endometrial Neoplasms / surgery. Female. Humans. Medical Records. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686373.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, Kwon KA, Lee S, Lee HS, Kim HJ: Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol; 2010 Dec;6(4):278-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
  • We evaluated the efficacy and toxicity of adjuvant chemoradiation versus chemotherapy in completely resected locally advanced gastric cancer.
  • METHODS: Patients with stage IIIA, IIIB and IV (without metastasis) gastric cancer were treated with chemoradiation and 5-fluorouracil/cisplatin (FP) (arm A) or FP (arm B).
  • CONCLUSION:   We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Liver Neoplasms / therapy. Lymph Node Excision. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Capecitabine. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Asia Pty Ltd.
  • [CommentIn] Asia Pac J Clin Oncol. 2011 Jun;7(2):93-5 [21585687.001]
  • (PMID = 21114777.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Bristow RE, del Carmen MG, Kaufman HS, Montz FJ: Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg; 2003 Oct;197(4):565-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer.
  • BACKGROUND: The aim of this study was to describe the feasibility, associated morbidity, and efficacy of radical oophorectomy with primary stapled colorectal anastomosis among patients with locally advanced ovarian cancer with contiguous extension to or encasement of the reproductive organs, pelvic peritoneum, cul-de-sac, and sigmoid colon.
  • STUDY DESIGN: Thirty-one consecutive patients undergoing radical oophorectomy as part of an initial maximal surgical effort for International Federation of Obstetrics and Gynecology (FIGO) stage IIIB-IV ovarian cancer were prospectively collected from October 1, 1997 through November 30, 2001.
  • All patients had advanced-stage epithelial ovarian cancer: FIGO stage IIIB (6.5%), stage IIIC (64.5%), stage IV (29.0%).
  • Median operating time was 240 minutes (range 165 to 330 minutes), and the median estimated blood loss was 700 mL (range 300 to 2,900 mL).
  • Thirty patients received multiagent platinum-based chemotherapy, with a median overall survival time of 39.5 months.
  • CONCLUSIONS: Radical oophorectomy with primary stapled anastomosis is an effective technique for resection of locally advanced ovarian cancer and contributes significantly to a maximal cytoreductive surgical effort.
  • [MeSH-major] Colon / surgery. Ovarian Neoplasms / surgery. Ovariectomy / methods. Rectum / surgery


11. Soegaard Andersen E, Knudsen A, Svarrer T, Lund B, Nielsen K, Grove A, Tetsche M: The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol; 2005 Dec;99(3):552-6
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark.
  • OBJECTIVE: The study was performed to evaluate the results of treatment of ovarian carcinoma after the introduction of centralised primary surgery in the County of North Jutland, Denmark.
  • METHOD: Prospective study of consecutive cases of ovarian cancer undergoing primary surgical treatment at the Gynecologic Oncologic Center after the introduction of centralised primary surgery.
  • Results of treatment recorded up to the date of last examination or death.
  • RESULTS: From 1999 to 2002, 107 patients with primary epithelial ovarian cancer underwent primary surgery at the Gynecologic Oncologic Center, Aalborg.
  • This corresponds to 95.5% of patients with invasive carcinoma in the County of North Jutland.
  • All patients with Stage I to Stage IIIB disease had a complete, macroscopically radical cytoreduction performed.
  • In patients with Stage III and IV invasive tumors, the optimal debulking rate was 79.5%, and, in Stage IIIC and IV, the optimal debulking rate was 78.2%.
  • After primary surgery, platinum-based chemotherapy was given in most cases.
  • For Stage I to IV invasive cancer, the median survival was 46 months.
  • In patients with Stage IIIC and IV disease, the median survival was 32 months.
  • In optimally debulked Stage IIIC and IV disease, the median survival was 41 months.
  • Compared to existing national and regional data on survival in ovarian cancer, the results indicate an increase in median survival for all stages of approximately 15 months.
  • Centralisation of primary surgery to centres with the necessary expertise may be the most significant way to increase survival in ovarian cancer in Denmark.
  • [MeSH-major] Ovarian Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Busulfan / analogs & derivatives. Busulfan / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Combined Modality Therapy. Denmark. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150480.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Ochiai K, Kuramoto H, Yamashita K, Tanaka KI, Saito T, Hiura M, Mizutani K, Hoshiai H, Teramukai S, Tada H: The impact of therapeutic modalities on the outcome of advanced epithelial ovarian cancer patients treated in Japan. A JMTO study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of therapeutic modalities on the outcome of advanced epithelial ovarian cancer patients treated in Japan. A JMTO study.
  • : 5097 Background: The basic treatment strategy of advanced epitherial ovarian cancer (EOC) patients is the combination of maximal surgical debulking and platinum-based adjuvant chemotherapy.
  • The purpose of this study was to assess the impact of treatment modalities on the outcome of stage III and IV EOC patients treated in Japan between 1994 and 2000.
  • The FIGO stage and number of patients were IIIa 24, IIIb 64, IIIc 471 and IV 135, respectively.
  • Among prognostic factors we studied, performance status (p=0.0001), FIGO stage (p=0.0001), nodal status (p=0.043), distant metastasis (p=0.0001) did, but overall histopathology (p=0.116) and histological grade (p=0.37) did not affect overall survival (OS) and progression free survival (PFS).
  • Clear cell and mucinous types were significantly worse than other histological cell types on OS (p=0.006) but not on PFS (p=0.192).
  • Five year survival rates (5YSR) according to the first-line chemotherapy were as follows: CAP (cyclophosphamide + doxorubicin + cisplatin) (n=190): 50.1%, CP or CJ(C + carboplatin) (n=71): 43.7%, TP or TJ (taxol + P or J) (N=193): 44.4%, and there were no significant impact on OS and PFS.
  • CONCLUSIONS: Surgical debulking of intra-abdominal tumor mass is the most important procedure to improve the prognosis of advanced EOC patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kirby TO, Straughn JM, Bhoola SM, Alvarez RD, Huh WK: Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy.
  • This study assessed the risk of recurrence of advanced stage epithelial ovarian cancer patients after complete response to taxane/platinum-based chemotherapy.
  • METHODS: Patients with epithelial ovarian cancer treated with taxane/platinum-based chemotherapy from 1994 - 2001 were identified from the medical records.
  • Complete response was defined as having pathologically negative SLL with a post-treatment CA125 of <35 IU.
  • RESULTS: Sixty-six patients with a negative SLL and normal post-treatment CA125 were identified.
  • 37 of the 66 patients (56%) with a negative SLL recurred, and specfically 31 of 43 (72%) stage IIIc/IV patients recurred.
  • Five-year disease free survival (DFS) for stages IIIc/IV was significantly worse than stage I-IIIb (25% vs. 63%, p=0.02).
  • Five-year overall survival was 61% and 87% (p=0.13) for stage IIIc/IV and stage I-IIIb, respectively.
  • Median DFS of stage IIIc/IV was 27 months with a median time to recurrence of 16 months (range 4-61 months).
  • CONCLUSIONS: Taxane/platinum treated stage IIIc/IV patients who have a negative SLL have high rates of recurrence (72%).
  • Despite complete response to primary therapy, advanced stage disease at initial diagnosis confers a poor prognosis.
  • This data would further substantiate abandonment of second look laparotomy and the investigation of maintenance therapies in this population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Arca R, Ibarra J, Lerzo G, Mandachain M, Mickievicz E, Perez J, Richardet E, Rodger J, Van Kooten M, Orlando M: Gemcitabine (GEM) + oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): Preliminary report of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine (GEM) + oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): Preliminary report of a phase II study.
  • : 5111 Background: GEM is active in recurrent epithelial ovarian cancer.
  • OX activity in ovarian cancer is similar to cisplatin in first-line therapy and PAC in nonrefractory relapses.
  • This multicenter, prospective phase II study combines GEM/OX as first-line sequential therapy for advanced ovarian cancer in pts after 3 cycles of CB/PAC.
  • Primary endpoint is time to disease progression; secondary endpoints are CA 125 response rate, objective response, response duration, overall survival, correlation between expression of MMR and p53 and efficacy, and toxicity.
  • METHODS: Pts with confirmed histologic diagnosis of stage III/IV epithelial ovarian carcinoma, initial surgery including anexohysterectomy + omentectomy, 3 cycles of CB ≥AUC 5 and PAC ≥175 mg/m<sup>2</sup>, no other prior chemotherapy, and adequate organ and marrow function were enrolled.
  • 8 pts had stage IIIB; 7, stage IIIC; 3, stage IV.
  • No treatment-related deaths occurred.
  • CONCLUSIONS: GEM/OX following CB and PAC is feasible, with minimal and manageable toxicity, in pts with ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Deplanque G, Goupil A, Fabbro M, Levy E, Rixe O, Benettaib B, Cvitkovic E: Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results. J Clin Oncol; 2004 Jul 15;22(14_suppl):5075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results.
  • : 5075 Background: Despite the introduction of paclitaxel/platinum combinations in first line treatment of AOC, a small proportion of patients fail to respond.
  • METHODS: AOC pts with histologically proven stage IIc or IIIa-c after maximal debulking surgery (microscopic disease or macroscopic disease ≤2 cm) performed 2-7 weeks before study treatment start, received 175 mg/m<sup>2</sup> P, 3-hour intravenous infusion, followed by 130 mg/m<sup>2</sup> OXA, 2-hour intravenous infusion, every 3 weeks, on an outpatient basis, without G-CSF.
  • Pts with positive histology after second look surgery could receive up to 2 further cycles; pts with pathological complete response received no further treatment.
  • RESULTS: Between Aug 2001 and Jan 2003, 17 pts were entered in 9 centres (49 planned), 14 eligible, 3 ineligible (2 colorectal cancer with peritoneal presentation, 1 pre-treated with OXA/cisplatin/P).
  • Median age 59 years (range 40-68); Performance status 0/1/2: 10/3/1; histology serous: 11, other: 3; FIGO stage IIIb: 5, IIIc: 9; microscopic residual disease: 3, macroscopic: 11.
  • CONCLUSION: The OXA/P combination shows high antitumor activity and a safe toxicity profile in first-line treatment for AOC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015559.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sikov WM: Locally advanced breast cancer. Curr Treat Options Oncol; 2000 Aug;1(3):228-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer.
  • Over the past 20 years, the prognosis for women diagnosed with locally advanced breast cancer (LABC; clinical stages IIB through IIIB) has improved significantly with recognition of the efficacy of multimodal therapy for reducing both local and distant recurrences, even in patients with inflammatory breast cancer (IBC).
  • Most patients will respond to induction, or neoadjuvant, chemotherapy (NAC) with an anthracycline-based regimen, enabling many patients with large but operable tumors to undergo breast-conserving surgery (BCS) and enabling resection in most patients with inoperable disease.
  • The addition of paclitaxel or docetaxel, either in combination with an anthracycline or as a separate regimen administered before or after anthracycline-based therapy, increases clinical and pathologic response rates and may improve DFS.
  • Patients who received only anthracycline-based NAC who are found to have significant residual disease in the breast or involved axillary nodes at surgery should receive adjuvant chemotherapy with paclitaxel.
  • Adjuvant hormonal therapy with tamoxifen improves DFS and OS in patients with hormone receptor (HR)-positive tumors, and ovarian ablation should be considered in premenopausal patients with HR-positive tumors and multiple involved nodes or stage IIIB disease.
  • Neoadjuvant hormonal therapy with either tamoxifen or an aromatase inhibitor may benefit frail or elderly patients with HR-positive tumors for whom chemotherapy is not an option.
  • No advantage has been demonstrated for high-dose chemotherapy requiring hematopoietic stem-cell support as either NAC or adjuvant therapy in LABC.
  • Newer treatment approaches, including trastuzumab (Herceptin, Genentech, Inc., South San Francisco, CA), in patients with Her-2-overexpressing tumors or other biologic agents, do not have a proven role in the management of LABC at this time.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Female. Hormones / therapeutic use. Humans. Neoplasm Recurrence, Local / secondary. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prognosis. Radiotherapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Mar;17(3):1080-2 [10071303.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):449-56 [10507769.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):452-61 [9309333.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1138-49 [9070491.001]
  • [Cites] Surg Clin North Am. 1996 Apr;76(2):411-29 [8610272.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(4):321-9 [9225950.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):72-8 [10400039.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):875-80 [9531373.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3412-7 [10550135.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):466-76 [8004622.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3033-7 [10506597.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):771-6 [8478670.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):207-15 [8996144.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):211-8 [9024070.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2366-72 [9635529.001]
  • [Cites] Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31 [9554929.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1019-28 [8600084.001]
  • (PMID = 12057165.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hormones
  • [Number-of-references] 30
  •  go-up   go-down


17. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z: Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA; 2001 Sep 26;286(12):1490-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm.
  • CONTEXT: In reproductive-age women, one of the common adverse effects of chemotherapy and radiotherapy is premature ovarian failure.
  • OBJECTIVE: To develop an ovarian transplantation technique to preserve endocrine function in women undergoing sterilizing radiotherapy and/or chemotherapy, or oophorectomy.
  • DESIGN AND SETTING: Case study of 2 patients in New York who received autologous ovarian transplantation (patient A, November 1999; patient B, April 2000) to the forearm prior to pelvic radiotherapy or after oophorectomy.
  • PARTICIPANTS: Patient A is a 35-year-old woman with stage IIIB squamous cell cervical carcinoma and patient B is a 37-year-old woman with recurrent benign ovarian serous cysts.
  • The mean (SE) follicle-stimulating hormone and luteinizing hormone levels decreased to 8.6 (0.4) mIU/mL and 12.8 (0.8) mIU/mL, respectively.
  • The peripheral estradiol levels showed cyclical variation (mean [SE], 115 [9.2] pg/mL [422 (33.8) pmol/L), and during the 18-month follow-up, a dominant follicle developed each month.
  • The estradiol levels from the right cubital vein were consistent with ovarian vein measurements (mean [SE], 1069 [269] pg/mL [3924 (987.5) pmol/L]).
  • In patient B, ovarian function was demonstrated by ultrasound visualization of a 9-mm follicle by 6 months after transplantation.
  • Ovulation was further confirmed by midluteal progesterone measurements (range, 7-10.1 ng/mL; mean [SE], 8.5 [0.9] ng/mL).
  • Patient B's ovarian graft was still functional 10 months after the transplantation.
  • CONCLUSIONS: Subcutaneous ovarian transplantation appears to be a relatively simple, novel technique to preserve endocrine function in women undergoing sterilizing cancer therapy or surgery.

  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2002 Jan 2;287(1):44-5 [11754702.001]
  • (PMID = 11572742.001).
  • [ISSN] 0098-7484
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


18. Joly F, Héron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhommé C, Macé-Lesec'h J, Crouet H: High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol; 2000 Sep;78(3 Pt 1):361-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
  • OBJECTIVE: The aim of this study was to evaluate the impact of platinum dose intensity on pathological response rate and overall survival in patients with advanced ovarian adenocarcinoma.
  • METHODS: Between February 1992 and December 1996, 195 previously untreated patients with FIGO stage IIb-c, IIIb-c, or IV with macroscopic residual disease after suboptimal debulking surgery were randomized to receive CCC (100 mg/m(2) of cisplatin, 300 mg/m(2) of cyclophosphamide, 300 mg/m(2) of carboplatin, n = 96) or CC (100 mg/m(2) of cisplatin, 600 mg/m(2) of cyclophosphamide, n = 99) for six courses at 28-day intervals.
  • A second-look laparotomy was planned at the end of chemotherapy.
  • With a median follow-up of 53 months, the median time to failure and the 3-year treatment failure-free survival rate were 17.4 months and 22% vs 13 months and 11% in the two arms, respectively (P = 0.01).
  • The median survival time and the 3-year overall survival rate were, respectively, 30 months and 42% vs 25 months and 33% (P < 0.20).
  • CONCLUSION: The platinum dose intensification (1.6-fold increase) obtained with the CCC association improves the treatment failure-free survival without significant impact on overall survival when compared with the CC regimen in suboptimal debulked ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10985895.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; CCC protocol; CP protocol
  •  go-up   go-down


19. Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, Haberstroh M, Neunhoeffer T, Barinoff J, Gomez R, Traut A, du Bois A: Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol; 2010 Jan;17(1):279-86
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
  • BACKGROUND: Treatment of advanced-stage ovarian carcinoma includes radical cytoreductive surgery, which aims at removing all visible tumor tissue followed by platinum and paclitaxel chemotherapy.
  • This paper reports on the prognostic impact of extensive surgery and surgical morbidity in patients with advanced-stage ovarian carcinoma.
  • METHODS: Patients with ovarian carcinoma [Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IIIB-IV] undergoing primary surgery in our tertiary gynecologic oncology unit between 1997 and 2007 were eligible for this study.
  • Overall survival time was improved in patients who underwent complete tumor resection [hazard ratio (HR) 3.61 (1.91-6.61), P < 0.001].
  • [MeSH-major] Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898901.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L: Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):26-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hepatic metastasis in patients with ovarian cancer.
  • The purpose of this study was to investigate the clinical features of hepatic metastasis in patients with epithelial ovarian cancer.
  • From 1998 to 2002, all women with hepatic metastasis from ovarian cancer were identified at the University of Bari.
  • Twenty-nine patients identified included one having stage IIC, one stage IIIA, two stage IIIB, 17 stage IIIC, and eight stage IVB.
  • Eight women had hepatic metastasis at the time of the diagnosis of ovarian cancer (group I), 10 patients had hepatic metastasis as first recurrence (group II), and 11 (group III) as a second relapse.
  • The median survival from the time of liver metastasis diagnosis was 19 months in group I patients, 24 months in group II patients, and 10 months in group III patients.
  • Cell type, performance status at the time of the primary tumor diagnosis, number of hepatic lesions, the presence of other sites of disease at the time of hepatic metastasis, and platinum-based chemotherapy were significantly related to survival.
  • Better performance status, serous cell-type tumor, single hepatic lesion, the absence of other sites of disease, and platinum-based chemotherapy are good prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670293.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH: Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):342-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.
  • Borderline ovarian tumors account for 15% of epithelial ovarian cancers and are different from invasive malignant carcinoma.
  • Majority are early stage, occurring in women in the reproductive age group, where fertility is important.
  • Majority of the cases (92%) were FIGO stage I (Ia, 75%; Ib, 1%; and Ic, 16%).
  • Seven (3.5%) patients were diagnosed as having stage II disease, six (2.5%) as stage IIIa, two (1%) as stage IIIb, and four (2%) as stage IIIc.
  • Primary surgical procedures undertaken were as follows: hysterectomy with bilateral salpingo-oophorectomy (52%), unilateral salpingo-oophorectomy (33%), or ovarian cystectomy (15%).
  • Adjuvant chemotherapy was administered in 13 patients (5.2% of cases), of which 4 patients were given chemotherapy only because of synchronous malignancies.
  • Overall mean time to recurrence was 59 months.
  • There were a total of five deaths (2.8%): three (1.5%) from invasive ovarian/peritoneal carcinoma and two from synchronous uterine malignancies.
  • It appears that surgical resection is the mainstay of treatment, with conservative surgery where fertility is desired or pelvic clearance if the family is complete.
  • The role of adjuvant chemotherapy is not established.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343573.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hamid D, Rohr S, Baldauf JJ, Ritter J, Kurtz E, Dufour P, Meyer P, Minetti A, Meyer C: [Interest in intestinal resection for treatment of advanced ovarian cancer]. Ann Chir; 2002 Jan;127(1):40-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interest in intestinal resection for treatment of advanced ovarian cancer].
  • [Transliterated title] Intérêt des exérèses digestives dans le traitement des cancers évolués de l'ovaire.
  • AIM OF THE STUDY: Digestive surgery is often necessary for surgical management of advanced ovarian carcinoma.
  • PATIENTS AND METHODS: In a series of 62 patients with stage III ovarian carcinoma, postoperative morbidity and mortality, overall survival after 5 years and disease-free survival after 2 years were studied and corelated with several patients criteria (age, stage of the disease, residual disease, type of surgery, CA125 normalisation delay, postoperative complications and hospital stay).
  • Patients were divided into two groups according to the surgical treatment.
  • All patients were proposed for chemotherapy included platyn salt.
  • The stage of the cancer was stage IIIa in 7 cases, stage IIIb in ten and stage IIIc in 45.
  • CONCLUSION: This study including 62 patients confirmed the prognostic significance of extensive cytoreductive surgery for treatment in advanced ovarian epithelial cancer without increasing the postoperative morbidy and mortality.
  • [MeSH-major] Digestive System Surgical Procedures. Neoplasm Invasiveness. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11833305.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Kilic-Okman T, Yardim T, Gücer F, Altaner S, Yuce MA: Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome. Arch Gynecol Obstet; 2008 Jul;278(1):75-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome.
  • In 2003, concomitant to cervical carcinoma, breast cancer was diagnosed.
  • Patient underwent left modified radical mastectomy due to the invasive papillary carcinoma.
  • The patient received six cycles combination chemotherapy and radiation therapy because of stage IIIB cervical cancer.
  • CONCLUSION(S): This is the first case report presenting PJS associated with multiple genital tract tumors including ovarian gonadoblastoma in literature.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gonadoblastoma / diagnosis. Ovarian Neoplasms / diagnosis. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Biomarkers, Tumor / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Fatal Outcome. Female. Humans. Mastectomy. Neoplasms, Multiple Primary


24. Kurihara M, Sakamoto H, Ohta Y, Takami T, Takami M, Nakayama Y, Murata H, Ohtani K, Masaoka N, Yamamoto T, Satoh K: [Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women]. Gan To Kagaku Ryoho; 2001 Jan;28(1):55-61
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women].
  • OBJECTIVES: To assess patient compliance and efficacy of a combination chemotherapy consisting of weekly administration of paclitaxel and carboplatin for gynecologic malignancy in Japanese women.
  • METHODS: Fourteen ovarian and three uterine cancer patients received 80 mg/m2 of paclitaxel (paclitaxel) and AUC 1.5 to 2.0 of carboplatin weekly.
  • One patient with stage IIIb cervical cancer underwent postchemotherapy-hysterectomy and a complete pathological response was confirmed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Patient Compliance. Quality of Life
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11201381.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Adis International Ltd: Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Drugs R D; 2003;4(4):243-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is one of a class of anticancer drugs that target the underlying molecular mechanism involving oncogenes and tumour suppressor genes, which play critical roles in the conversion of normal cells into a cancerous state.
  • OSI will keep certain co-promotion rights in the US and Genentech will be responsible for commercialising the drug in the US should the FDA approve it.
  • Initially, the alliance partners intend to pursue development of erlotinib in all the major tumour markets, particularly for non-small cell lung cancer (NSCLC) in which the group will focus on front-line combination approaches.
  • Pfizer and OSI Pharmaceuticals in the US were developing erlotinib as a treatment for solid tumours.
  • This divestiture of the erlotinib portfolio, in effect, gave OSI a royalty-free, cashless license to the drug.
  • The partnership will enable OSI to heighten awareness of its clinical trials and shorten patient accrual times.
  • OSI has also entered into an agreement with Therradex, a contract research organisation (CRO) to monitor phase II trials for erlotinib in NSCLC, ovarian and head and neck cancer.
  • The multicentre study is being conducted by Genentech in 1000 patients in the US, and will determine whether the addition of erlotinib to carboplatin chemotherapy is able to improve the duration of patient survival.
  • However, the DMC did recommend stopping erlotinib at the time of disease progression or at the start of second-line therapy.
  • A front-line phase III study of erlotinib in NSCLC (TALENT) in combination with gemcitabine and cisplatin chemotherapy was initiated by Roche in Europe in November 2001.
  • Roche has confirmed that the study woulde has confirmed that the study would be included in the alliance's potential regulatory submission for front-line therapy in chemotherapy-naive patients in the US.
  • A phase I study of erlotinib is also being conducted in patients with lung cancer in Japan.
  • OSI received fast-track status from the US FDA in September 2002 for erlotinib as a second- or third-line treatment for patients with incurable stage IIIB/IV NSCLC who have failed to respond to standard therapy for advanced metastatic disease.
  • Fast-track status was also granted to erlotinib in May 2002 for the treatment of chemotherapy-naive stage III/IV NSCLC.
  • There are important differences between phase III studies of erlotinib and AstraZeneca's direct competitor drug gefitinib, which recently returned disappointing results in a frontline NSCLC trial with combination chemotherapy.
  • In assessing the survival benefit of erlotinib with chemotherapy, the dose employed of 150 mg/day is the maximum tolerated dose (MTD), whereas the gefitinib trials were conducted at relatively lower doses than the MTD determined in earlier phase I studies.
  • Patient size of the NSCLC trial was increased from 330 to 700 as OSI shifted emphasis from its pancreatic cancer trials.
  • The NCI is developing erlotinib through its CTEP programme for multiple tumour types including epithelial malignancies, gastrointestinal and genitourinary tracts, gynaecological malignancies and brain tumours.
  • In an earlier report by the Financial Times on 10 May 2001, it was stated that approximately 12 new anticancer agents are expected to be approved by the FDA through to the end of 2002.
  • Goldman Sachs have forecast Tarceva to reach peak sales of $US250 million for the indication of head and neck cancer alone.
  • Previously in January 2001, the Financial Times claimed that OSI Pharmaceuticals, one of the development partners for Tarceva, stood to gain $US187 million pending regulatory approval.
  • Tarceva is facing competition by two similar compounds, developed by AstraZeneca and ImClone, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Administration, Oral. Clinical Trials as Topic. Costs and Cost Analysis. Drug Industry / economics. Erlotinib Hydrochloride. Humans. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12848590.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


26. Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G: Weekly paclitaxel in elderly patients (aged &gt; or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer; 2008 Sep;9(5):280-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
  • PURPOSE: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC).
  • In recent years, weekly paclitaxel has been widely used for its safety profile, especially in breast and ovarian cancer.
  • The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
  • PATIENTS AND METHODS: Twenty-seven patients entered the study; 10 had stage IIIB disease (5 "wet" and 5 "dry"), and 17 had stage IV disease.
  • Median time to progression was 5 months (range, 1-23 months), and median survival was 12 months (range, 1-36 months).
  • CONCLUSION: Our study confirmed that paclitaxel 80 mg/m2 weekly is active in patients with locally advanced and metastatic NSCLC with a good safety profile; this schedule might be considered an alternative choice to gemcitabine or vinorelbine as first-line treatment in elderly patients, particularly patients with comorbidities.
  • Phase III studies that compare these third-generation drugs are warranted to draw definitive conclusion about the best approach in these patients.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Prognosis. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824450.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE, University of Chicago Phase II Network, Ohio State University: A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol; 2004 Jun;15(6):915-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
  • PURPOSE: To evaluate the efficacy and toxicity of oxaliplatin and paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: The treatment regimen was given as defined in a phase I investigation in patients with previously treated ovarian cancer.
  • Eligible patients had stage IIIB (pleural effusion)/IV NSCLC, measurable disease, no prior chemotherapy, Eastern Cooperative Oncology Group performance status 0-2, and adequate hematological, renal and hepatic function.
  • RESULTS: A total of 38 patients were enrolled with the following characteristics: 29% male (n = 11); 71% female (n = 27); median age 64.5 years (range 37-78); performance status of 0-1 84% (n = 32); stage IIIB 8% (n = 3); stage IV 92% (n = 35).
  • Median overall survival time was 9.2 months (95% CI 6-12.4) and median progression-free survival time was 4.3 months (95% CI 2.1-6.5).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15151948.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA016058; United States / NCI NIH HHS / CM / CM107102-02; United States / NCI NIH HHS / CA / U01CA63187-01
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement